Business
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed
About this update from Jade Biosciences, Inc.
[{"type":"image","alt":"Jade Biosciences","displaySize":"","headline":null,"caption":"Jade Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DtRhwV3KjbfNt1TBBxBOZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DtRhwV3KjbfNt1TBBxBOZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Interim Phase 2 JADE101 data are expected in 2027","length":49,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":49,"olType":false},{"type":"text","content":"SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient’s lifetime. Interim data from JUNIPER are expected in 2027.","length":748,"tagName":"p"},{"type":"text","content":"“Maximizing the clinical benefit of the anti-APRIL mechanism and delivering a convenient dosing profile, requires optimized potency and durability,” said Andrew King, Ph.D., President of Research and Development at Jade Biosciences. “Preclinical data showed JADE101 has ultra-high binding affinity to APRIL and a differentiated pharmacokinetic and pharmacodynamic profile, supporting the potential to drive deep and sustained IgA reductions and enable patient-friendly subcutaneous dosing of no more frequently than every eight weeks. We look forward to continuing to advance JADE101 in the Phase 2 JUNIPER trial.”","length...